These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

649 related items for PubMed ID: 31711387

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK.
    Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D, Palaka E, Bennett H, McEwan P.
    ESC Heart Fail; 2019 Apr; 6(2):280-290. PubMed ID: 30629342
    [Abstract] [Full Text] [Related]

  • 3. Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink.
    Furuland H, McEwan P, Evans M, Linde C, Ayoubkhani D, Bakhai A, Palaka E, Bennett H, Qin L.
    BMC Nephrol; 2018 Aug 22; 19(1):211. PubMed ID: 30134846
    [Abstract] [Full Text] [Related]

  • 4. Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis.
    Jiménez-Marrero S, Cainzos-Achirica M, Monterde D, Vela E, Enjuanes C, Yun S, Garay A, Moliner P, Corbella M, Jovells-Vaqué S, Alcoberro L, Pons-Riverola A, Ramos-Polo R, Morillas H, Gómez-Hospital JA, Comin-Colet J.
    Eur J Intern Med; 2024 Jul 22; 125():89-97. PubMed ID: 38548513
    [Abstract] [Full Text] [Related]

  • 5. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
    Jun M, Jardine MJ, Perkovic V, Pilard Q, Billot L, Rodgers A, Rogers K, Gallagher M.
    PLoS One; 2019 Jul 22; 14(3):e0213192. PubMed ID: 30845156
    [Abstract] [Full Text] [Related]

  • 6. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
    Johnson M, Morrison FJ, McMahon G, Su M, Turchin A.
    Am Heart J; 2023 Apr 22; 258():49-59. PubMed ID: 36642227
    [Abstract] [Full Text] [Related]

  • 7. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
    Garlo KG, Bates DW, Seger DL, Fiskio JM, Charytan DM.
    JAMA Netw Open; 2018 Nov 02; 1(7):e183874. PubMed ID: 30646338
    [Abstract] [Full Text] [Related]

  • 8. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
    An J, Zhou H, Ni L, Harrision TN, Wei R, Agiro A, Brahmbhatt YG, Oluwatosin Y, Schilling CG, Sim JJ.
    Am J Nephrol; 2023 Nov 02; 54(7-8):258-267. PubMed ID: 37231821
    [Abstract] [Full Text] [Related]

  • 9. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T, Lewis RD, Brown T, Baxter G, de Arellano AR.
    BMC Nephrol; 2023 Mar 09; 24(1):47. PubMed ID: 36890464
    [Abstract] [Full Text] [Related]

  • 10. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
    Polson M, Lord TC, Kangethe A, Speicher L, Farnum C, Brenner M, Oestreicher N, Alvarez P.
    J Manag Care Spec Pharm; 2017 Apr 09; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
    [Abstract] [Full Text] [Related]

  • 11. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
    Degli Esposti L, Perrone V, Giacomini E, Sangiorgi D, Alessandrini D, Santoro A.
    G Ital Nefrol; 2019 Sep 24; 36(5):. PubMed ID: 31580544
    [Abstract] [Full Text] [Related]

  • 12. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia.
    Kanda E, Rastogi A, Murohara T, Lesén E, Agiro A, Arnold M, Chen G, Yajima T, Järbrink K, Pollack CV.
    BMC Nephrol; 2023 Jan 19; 24(1):18. PubMed ID: 36658531
    [Abstract] [Full Text] [Related]

  • 13. Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review.
    Fonseca C, Brito D, Branco P, Frazão JM, Silva-Cardoso J, Bettencourt P.
    Rev Port Cardiol (Engl Ed); 2020 Sep 19; 39(9):517-541. PubMed ID: 32868174
    [Abstract] [Full Text] [Related]

  • 14. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure.
    Murphy D, Ster IC, Kaski JC, Anderson L, Banerjee D.
    BMC Nephrol; 2021 Jul 06; 22(1):254. PubMed ID: 34229607
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.
    Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J.
    Am J Manag Care; 2015 Sep 06; 21(11 Suppl):S212-20. PubMed ID: 26619183
    [Abstract] [Full Text] [Related]

  • 16. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
    Agiro A, An A, Cook EE, Mu F, Chen J, Desai P, Oluwatosin Y, Pollack CV.
    Adv Ther; 2023 Jun 06; 40(6):2886-2901. PubMed ID: 37140706
    [Abstract] [Full Text] [Related]

  • 17. Associations between serum potassium and adverse clinical outcomes: A systematic literature review.
    Palaka E, Grandy S, Darlington O, McEwan P, van Doornewaard A.
    Int J Clin Pract; 2020 Jan 06; 74(1):e13421. PubMed ID: 31532067
    [Abstract] [Full Text] [Related]

  • 18. DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.
    Karaboyas A, Xu H, Morgenstern H, Locatelli F, Jadoul M, Nitta K, Dasgupta I, Tentori F, Port FK, Robinson BM.
    Kidney Int; 2018 Sep 06; 94(3):589-598. PubMed ID: 29908836
    [Abstract] [Full Text] [Related]

  • 19. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC, Tromp J, Cleland JGF, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Ouwerkerk W, van Veldhuisen DJ, Voors AA, van der Meer P.
    JACC Heart Fail; 2019 Nov 06; 7(11):970-979. PubMed ID: 31606364
    [Abstract] [Full Text] [Related]

  • 20. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, Rosano GMC, Savarese G, Anker SD, Seferovic PM, Ruschitzka F, Coats AJS, Mebazaa A, McDonagh T, Sahuquillo A, Penco M, Maggioni AP, Lund LH, Heart Failure Long-Term Registry Investigators Group.
    Eur J Heart Fail; 2020 Aug 06; 22(8):1378-1389. PubMed ID: 32243669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.